Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration

62Citations
Citations of this article
65Readers
Mendeley users who have this article in their library.

Abstract

Background. We determined temporal trends (1985-2011) in hepatitis C virus (HCV) incidence and associated behavioral exposures for people who inject drugs (PWID) from the United States (Boston, Baltimore, and San Francisco), Canada (Montreal), the Netherlands (Amsterdam), and Australia (Sydney and Melbourne). Methods. Using population-based cohort data from HCV-negative PWID, we calculated overall and within-city HCV incidence trends, HCV rates by study enrollment period (1985-2011), and temporal trends in exposure behaviors. Poisson regression models estimated trends in HCV incidence over calendar-time. Survival models identified risk factors for HCV incidence across cities and estimated independent effects of city and calendar period on HCV infection risk. Results. Among 1391 initially HCV-negative participants followed prospectively (1644.5 person-years of observation [PYO]), 371 HCV incident infections resulted in an overall incidence of 22.6 per 100 PYO (95% confidence interval [CI], 20.4-25.0). Incidence was highest and remained elevated in Baltimore (32.6/100 PYO), San Francisco (24.7/100 PYO), and Montreal (23.5/100 PYO), lowest in Melbourne and Amsterdam (7.5/100 PYO and 13.1/100 PYO, respectively), and moderate (21.4/100 PYO) in Sydney. Higher rates of syringe and equipment sharing and lower prevalence of opioid agonist therapy were associated with HCV incidence in cities with the highest incidence. Risk for infection dropped by 18% for every 3-year increase in calendar-time (adjusted hazard ratio, 0.8 [95% CI, .8-.9]) in the multivariable model. Conclusions. Differences in prevention strategies and injecting contexts may explain the ongoing high HCV incidence in these North American cities and emphasize the need for scale-up of opioid agonist therapy and increased coverage of needle and syringe programs in North America.

References Powered by Scopus

Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence

2097Citations
N/AReaders
Get full text

Needle exchange is not enough: Lessons from the Vancouver injecting drug use study

540Citations
N/AReaders
Get full text

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

450Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs

200Citations
N/AReaders
Get full text

Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis

194Citations
N/AReaders
Get full text

Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis

159Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Morris, M. D., Shiboski, S., Bruneau, J., Hahn, J. A., Hellard, M., Prins, M., … Page, K. (2017). Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration. Clinical Infectious Diseases, 64(7), 860–869. https://doi.org/10.1093/cid/ciw869

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 25

54%

Researcher 14

30%

Professor / Associate Prof. 6

13%

Lecturer / Post doc 1

2%

Readers' Discipline

Tooltip

Medicine and Dentistry 16

57%

Nursing and Health Professions 4

14%

Social Sciences 4

14%

Agricultural and Biological Sciences 4

14%

Article Metrics

Tooltip
Mentions
News Mentions: 2
Social Media
Shares, Likes & Comments: 2

Save time finding and organizing research with Mendeley

Sign up for free